Celcuity CEO to Present at Guggenheim Biotech Summit 2026
Event summary
- Celcuity CEO Brian Sullivan to participate in fireside chat on February 11, 2026, at Guggenheim Biotech Summit 2026.
- Live webcast available via company website and summit link.
- Celcuity's lead therapeutic candidate is gedatolisib, a pan-PI3K and mTORC1/2 inhibitor.
- Phase 3 trial VIKTORIA-1 completed enrollment; results reported for PIK3CA wild-type cohort.
- Phase 3 trial VIKTORIA-2 and Phase 1/2 trial CELC-G-201 currently enrolling patients.
The big picture
Celcuity's participation in the Guggenheim Biotech Summit 2026 underscores its focus on advancing targeted therapies for oncology. The company's lead candidate, gedatolisib, aims to address multiple solid tumor indications, positioning Celcuity in a competitive landscape of PI3K/AKT/mTOR pathway inhibitors. The strategic significance lies in the potential for gedatolisib to differentiate itself through its comprehensive blockade of the PAM pathway, which could attract investor attention and partnerships.
What we're watching
- Clinical Trial Progress
- How the completion of VIKTORIA-1 and ongoing enrollment in VIKTORIA-2 will impact Celcuity's strategic positioning.
- Therapeutic Differentiation
- Whether gedatolisib's differentiated mechanism of action can drive competitive advantage in the oncology market.
- Investor Sentiment
- The pace at which investor interest and market valuation respond to Celcuity's clinical trial updates and conference presence.
Related topics